PD-1 monoclonal antibody (tirelizumab) monotherapy or combination regimen for the treatment of extranodal NK/T cell lymphoma in children: a prospective, open-label real-world study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033625

Enrollment

Unknown

Registered

2020-06-07

Start date

2020-06-05

Completion date

Unknown

Last updated

2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extranodal NK/T cell lymphoma in children

Interventions

Case series:Intravenous tislelizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 1.5cm; or the longest diameter of extranodal lesions> 1.0cm; 4. Have traceable medical history records during treatment; 5. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up.

Exclusion criteria

Exclusion criteria: 1. With hemophilia syndrome; 2. Previously used allogeneic hematopoietic stem cell transplantation; 3. According to the investigator's judgment, the patient may have other factors that may lead to the forced termination of the study, such as other serious diseases or severe laboratory abnormalities or accompanied by other factors that will affect the safety of the subject, or test data and samples Collect family or social factors.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics;Clinical safety;Clinical efficacy;	—

Countries

China

Contacts

Public ContactYonghong Zhang

Beijing Boren Hospital

zhangyh@borenhospital.com+86 13701251969

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026